总时间（秒）：15.60
问答时间（秒）：14.02

Based on the provided literature, I will extract and standardize the relevant information according to the specified JSON framework.

**Variants Include**
```json
{
  "Variants Include": [
    {
      "Gene": "a-synuclein",
      "variants": [
        {
          "HGVS": "NM_002040.3:c.56-102del",
          "cDNA Change": {
            "transcript": "NM_002040.3",
            "ref": "N/A",
            "alt": "del",
            "position": "56-102"
          },
          "Protein Change": {
            "ref": "N/A",
            "alt": "N/A",
            "position": "N/A"
          },
          "Description in input context": "Deletion of residues 56–102 (exon 4)"
        },
        {
          "HGVS": "NM_002040.3:c.130-140del",
          "cDNA Change": {
            "transcript": "NM_002040.3",
            "ref": "N/A",
            "alt": "del",
            "position": "130-140"
          },
          "Protein Change": {
            "ref": "N/A",
            "alt": "N/A",
            "position": "N/A"
          },
          "Description in input context": "Deletion of C-terminal residues 130–140 (exon 6)"
        }
      ]
    }
  ]
}
```

**Described Disease**
```json
{
  "Described Disease": {
    "Described Disease": "Parkinson’s disease",
    "MONDO": "MONDO:0005383"
  }
}
```
Note that I used the MONDO database to retrieve the corresponding term for Parkinson’s disease. If you would like me to use a different source or database, please let me know.

**Experiment Method**
```json
{
  "Experiment Method": [
    {
      "Assay Method": "In vitro assay",
      "Material used": {
        "Material Source": "Cell line",
        "Material Name": "N/A",
        "Description": "The experiment was conducted using a cell line."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_002040.3:c.56-102del",
          "Conclusion": "Abrogated PLD2 inhibition",
          "Molecular Effect": "N/A",
          "Result Description": "Deletion of residues 56–102 (exon 4) abrogates PLD2 inhibition."
        },
        {
          "Variant": "NM_002040.3:c.130-140del",
          "Conclusion": "Abrogated PLD2 inhibition",
          "Molecular Effect": "N/A",
          "Result Description": "Deletion of C-terminal residues 130–140 (exon 6) abrogates PLD2 inhibition."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Three biological replicates were performed."
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "Each sample was run in triplicate."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type cDNA was used as a positive control."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "Empty vector was used as a negative control."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N/A",
        "Counts": "N/A"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N/A",
        "Counts": "N/A"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "ANOVA was used for statistical analysis."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "PLD2 inhibition greater than 80%.",
        "Source": "Literature"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "PLD2 inhibition less than 50%.",
        "Source": "Literature"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    }
  ]
}
```
Please note that some fields, such as the material name and the counts of validation controls, were left blank or labeled as N/A since this information was not provided in the original literature. If you would like me to fill in these fields based on your own knowledge or assumptions, please let me know.